| The appropriate role of cost-effectiveness in determining device coverage: a case study of drug-eluting stents. | |
| | |
MedLine Citation:
|
PMID: 18997214 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The use of incremental cost-effectiveness ratios based on quality-adjusted life-years (QALYs) as a critical determinant of what should be covered by a health system is a growing trend. This presents challenges when applied to rapidly evolving technologies. The case study here focuses on the example of drug-eluting stents and the four-year change in cost-effectiveness as determined by the U.K. National Institute for Health and Clinical Excellence (NICE). We contend that classic cost-effectiveness as a blunt instrument for determining what should be covered may lead to erroneous conclusions when a broader perspective and the impact on health outcomes and costs are considered. |
| | |
Authors:
|
Brian Garriock Firth; Liesl M Cooper; Steve Fearn |
Related Documents
:
|
8476624 - High-cost, high-tech medicine: are we getting our money's worth? 10423054 - Cost utility analysis of prophylactic pamidronate for the prevention of skeletal relate... 1937944 - A research-oriented medical cost accounting system. 9093974 - Defining total corporate health and safety costs--significance and impact. review and r... 21946004 - Development of a web-based survey for monitoring daily health and its application in an... 12748454 - Early identification of mild traumatic brain injury in female victims of domestic viole... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Health affairs (Project Hope) Volume: 27 ISSN: 1544-5208 ISO Abbreviation: Health Aff (Millwood) Publication Date: 2008 Nov-Dec |
Date Detail:
|
Created Date: 2008-11-10 Completed Date: 2009-02-20 Revised Date: 2009-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 8303128 Medline TA: Health Aff (Millwood) Country: United States |
Other Details:
|
Languages: eng Pagination: 1577-86 Citation Subset: IM |
Affiliation:
|
Cordis Corporation, a Johnson and Johnson subsidiary in Warren, New Jersey, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Advisory Committees Cost-Benefit Analysis* Drug-Eluting Stents / economics* Great Britain Organizational Case Studies Quality-Adjusted Life Years Reimbursement Mechanisms* State Medicine |
| Comments/Corrections | |
Comment In:
|
Health Aff (Millwood). 2009 Mar-Apr;28(2):600-1; author reply 601
[PMID:
19276032
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Diffusion of new technology and payment policies: coronary stents.
Next Document: Hip and knee implants: current trends and policy considerations.